Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Acquired by AQR Capital Management LLC

AQR Capital Management LLC boosted its holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY) by 362.2% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 67,243 shares of the company’s stock after acquiring an additional 52,693 shares during the period. AQR Capital Management LLC owned 0.05% of Relay Therapeutics worth $438,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Logos Global Management LP acquired a new position in shares of Relay Therapeutics in the second quarter worth $8,476,000. Vanguard Group Inc. raised its stake in Relay Therapeutics by 10.9% in the 1st quarter. Vanguard Group Inc. now owns 11,815,669 shares of the company’s stock valued at $98,070,000 after purchasing an additional 1,165,282 shares during the last quarter. Marshall Wace LLP purchased a new position in Relay Therapeutics in the 2nd quarter valued at about $1,804,000. Candriam S.C.A. boosted its stake in shares of Relay Therapeutics by 38.4% during the 2nd quarter. Candriam S.C.A. now owns 703,429 shares of the company’s stock worth $4,586,000 after purchasing an additional 195,000 shares during the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of Relay Therapeutics by 19.1% during the second quarter. Renaissance Technologies LLC now owns 909,037 shares of the company’s stock worth $5,927,000 after buying an additional 145,837 shares in the last quarter. 96.98% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently issued reports on RLAY shares. JPMorgan Chase & Co. reduced their price objective on shares of Relay Therapeutics from $23.00 to $21.00 and set an “overweight” rating on the stock in a research note on Tuesday, September 10th. Oppenheimer cut Relay Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, September 10th. Jefferies Financial Group upgraded Relay Therapeutics from a “hold” rating to a “buy” rating and upped their target price for the company from $10.60 to $16.00 in a research note on Tuesday, September 10th. HC Wainwright reissued a “buy” rating and issued a $19.00 price target on shares of Relay Therapeutics in a research note on Monday. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $28.00 price objective on shares of Relay Therapeutics in a research note on Monday, September 16th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $21.11.

Relay Therapeutics Trading Down 0.1 %

Shares of Relay Therapeutics stock opened at $6.74 on Wednesday. Relay Therapeutics, Inc. has a twelve month low of $5.70 and a twelve month high of $12.14. The stock has a market cap of $902.42 million, a price-to-earnings ratio of -2.67 and a beta of 1.64. The company has a fifty day moving average price of $7.03 and a 200 day moving average price of $7.09.

Relay Therapeutics (NASDAQ:RLAY) last posted its earnings results on Tuesday, August 6th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.04. During the same period last year, the business posted ($0.81) earnings per share. Analysts forecast that Relay Therapeutics, Inc. will post -2.84 earnings per share for the current year.

Insider Buying and Selling at Relay Therapeutics

In other news, CFO Thomas Catinazzo sold 10,780 shares of the business’s stock in a transaction on Monday, July 29th. The shares were sold at an average price of $8.56, for a total transaction of $92,276.80. Following the transaction, the chief financial officer now directly owns 319,650 shares of the company’s stock, valued at approximately $2,736,204. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, CFO Thomas Catinazzo sold 10,780 shares of Relay Therapeutics stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $8.56, for a total transaction of $92,276.80. Following the sale, the chief financial officer now directly owns 319,650 shares of the company’s stock, valued at approximately $2,736,204. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Sanjiv Patel sold 36,706 shares of the stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $9.07, for a total value of $332,923.42. Following the completion of the transaction, the chief executive officer now directly owns 766,130 shares of the company’s stock, valued at $6,948,799.10. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 74,717 shares of company stock valued at $652,955 over the last 90 days. 4.32% of the stock is owned by corporate insiders.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.